NKX019 cell therapy for lupus
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study tests a new therapy called NKX019, which uses specially engineered natural killer cells to target a protein on lupus cells. It is for people with moderate to severe lupus that has not responded to standard treatments, especially those with active kidney inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- Your lupus must be active despite trying at least 2 prior treatments (one immunosuppressant and one biologic or advanced therapy).
- You need a lupus activity score of 8 or more, with at least 6 points from symptoms your doctor can measure.
- If you have lupus kidney disease, a recent biopsy must show active inflammation (Class III or IV) with significant protein in your urine.
- You must have positive blood tests for lupus (like ANA, anti-dsDNA, or anti-Smith antibodies).
- You must not have serious health issues like severe heart, lung, or kidney problems, active infections, or a history of certain cancers or past cell therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a special immune cell therapy (UCAR T-cells) that targets two proteins (CD19 and BCMA) on the surface of lupus B cells. It is for people with difficult-to-treat lupus that affects the kidneys (lupus nephritis) who have not gotten better with standard treatments.
This trial tests a new cell therapy called SNC116 for people with lupus that has not improved with standard treatments. The treatment aims to reset the immune system to reduce disease activity and may help those with severe lupus or kidney inflammation.
This trial tests a new cell therapy (RJMty19) for people with lupus that hasn't improved with standard treatments. It aims to reduce disease activity and may help those with active organ involvement.
This trial tests FT819, a new type of immune cell therapy (CAR T cells), for people with lupus nephritis—kidney inflammation caused by lupus—who haven't responded well to standard treatments. The goal is to see if this therapy can reduce kidney damage and improve kidney function.
This trial tests an experimental cell therapy called NKX019 for people with active lupus nephritis (a type of kidney inflammation from lupus) or primary membranous nephropathy (another kidney condition) that hasn't gotten better after standard treatments. It may help if you have tried at least two treatments for lupus kidney disease or one for membranous nephropathy and still have active kidney disease.
This trial tests a new type of immune cell therapy (called ES-NK cells) for people with a severe form of lupus nephritis that hasn't improved with standard treatments. The goal is to see if these cells can reduce kidney inflammation and improve lupus symptoms.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.